Literature DB >> 19258289

Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin.

Mathieu Milh1, Nathalie Villeneuve, Fréderique Chapon, Sandrine Pineau, Sylvie Lamoureux, Marie-Odile Livet, Céline Bartoli, Catherine Hugonenq, Josette Mancini, Brigitte Chabrol, Nadine Girard.   

Abstract

Vigabatrin is an antiepileptic drug that produces intramyelinic edema in several animal models. This study investigates the effect of vigabatrin on the developing human brain. The authors retrospectively blindly review 34 brain magnetic resonance imaging of 22 epileptic infants (age: 9 +/- 1 months) that received vigabatrin, focusing on the presence of hyperintensity on T2- and diffusion-weighted images. Patients treated with vigabatrin displayed significant magnetic resonance imaging hyperintensity of basal ganglia and brain stem (P < .001, Wilcoxon test). This hyperintensity was transient and maximal 3 to 6 months after the beginning of vigabatrin. Hyperintensity was independent from duration and type of epilepsy, and from the presence or absence of seizures. The authors conclude that vigabatrin treatment is associated with transient hypersignal of the basal ganglia and brain stem in epileptic infants. Such transient hyperintensity is likely to be age-dependent and time-dependent because it has never been observed in adult patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19258289     DOI: 10.1177/0883073808324219

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  12 in total

1.  T2 hyperintense signal of the central tegmental tracts in children: disease or normal maturational process?

Authors:  Sergio Aguilera-Albesa; Andrea Poretti; Dagmar Honnef; Meral Aktas; Maria Eugenia Yoldi-Petri; Thierry A G M Huisman; Martin Häusler
Journal:  Neuroradiology       Date:  2012-01-21       Impact factor: 2.804

2.  Evaluating risks for vigabatrin treatment.

Authors:  Gregory L Krauss
Journal:  Epilepsy Curr       Date:  2009 Sep-Oct       Impact factor: 7.500

Review 3.  The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.

Authors:  Paul LaPenna; Laura M Tormoehlen
Journal:  J Med Toxicol       Date:  2017-08-16

4.  Epilepsy. Genetics of early-onset epilepsy with encephalopathy.

Authors:  Rima Nabbout; Olivier Dulac
Journal:  Nat Rev Neurol       Date:  2012-01-31       Impact factor: 42.937

Review 5.  Magnetic resonance imaging patterns of treatment-related toxicity in the pediatric brain: an update and review of the literature.

Authors:  Maria Camilla Rossi Espagnet; Luca Pasquini; Antonio Napolitano; Antonella Cacchione; Angela Mastronuzzi; Roberta Caruso; Paolo Tomà; Daniela Longo
Journal:  Pediatr Radiol       Date:  2016-12-09

Review 6.  Magnetic resonance imaging of the brainstem in children, part 2: acquired pathology of the pediatric brainstem.

Authors:  Asha Sarma; Josh M Heck; Aashim Bhatia; Rekha S Krishnasarma; Sumit Pruthi
Journal:  Pediatr Radiol       Date:  2021-01-19

7.  Abnormal axial diffusivity in the deep gray nuclei and dorsal brain stem in infantile spasm treated with vigabatrin.

Authors:  G N Simao; S Zarei Mahmoodabadi; O C Snead; C Go; E Widjaja
Journal:  AJNR Am J Neuroradiol       Date:  2010-08-26       Impact factor: 3.825

8.  Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms.

Authors:  Jason T Lerner; Noriko Salamon; Raman Sankar
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-08       Impact factor: 2.570

9.  Magnetic resonance imaging differential diagnosis of brainstem lesions in children.

Authors:  Carlo Cosimo Quattrocchi; Yuri Errante; Maria Camilla Rossi Espagnet; Stefania Galassi; Sabino Walter Della Sala; Bruno Bernardi; Giuseppe Fariello; Daniela Longo
Journal:  World J Radiol       Date:  2016-01-28

10.  Treatment of refractory complex partial seizures: role of vigabatrin.

Authors:  Elizabeth J Waterhouse; Kimberly N Mims; Soundarya N Gowda
Journal:  Neuropsychiatr Dis Treat       Date:  2009-10-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.